Significance of chemokines and activated platelets in patients with diabetes

Abstract

SUMMARYLevels of platelet-derived microparticles (PMPs), platelet activation markers (P-selectin expressed on, or annexin V binding to, platelets (plt:P-selectin or plt:annexin V, respectively)), chemokines (IL-8, monocyte chemotactic peptide-1 (MCP-1), and regulated on activation normally T-cell expressed and secreted (RANTES)), and soluble P-and E-selectins were compared in peripheral blood from diabetic and control patients in order to develop a better understanding of their potential contribution to diabetic vascular complications. Significant increases were found for PMPs, plt:P-selectin, MCP-1, RANTES and soluble P-and E-selectins in diabetic individuals, whereas IL-8 levels were similar. Furthermore, after ticlopidine treatment, most of these factors receded to baseline levels observed in non-diabetic patients. Our findings indicate that ticlopidine might be able to prevent or reduce vascular complications in diabetic patients.

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002

“…Data from several studies linked MCP-1 and IL-8 to type 2 diabetes, but in particular data on IL-8 were based on rather small casecontrol studies [14,16]. Increased MCP-1 concentrations in type 2 diabetes patients were reported in a small Japanese case-control study [15], in elderly women selected from a population survey in Italy [17], in patients with prevalent cardiovascular disease [18,20] and in the population-based Dallas Heart Study [19]. Since the association of elevated MCP-1 levels and prevalent type 2 diabetes was not seen in the Dallas Heart Study when all individuals with subclinical atherosclerosis were excluded and was also absent in the cross-sectional KORA Survey 2000 [32], it remained unclear whether there was a link between MCP-1 and type 2 diabetes and how this relationship might be modulated by the concomitant presence of cardiovascular disease.…”

“…It has been postulated that chemokine expression might be an important step in the recruitment and activation of peripheral blood leucocytes in atherosclerotic lesions [12] and adipose tissue [13]. In particular elevated levels of MCP-1 and IL-8 may be associated with type 2 diabetes [14][15][16][17][18][19][20].…”

Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study

“…Etiology of HPR is complex, and seems to be a result of hyperglycemia, metabolic disorders, oxidative stress and inflammation [3]. In particular, T2DM patients have higher concentrations of inflammatory markers, platelet activation and coagulation markers than healthy subjects [4][5][6]. Moreover, higher concentrations of inflammatory markers correlate with increased CV risk [7,8].…”

Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus

“…18,19 Recently, we reported a correlation between levels of P-selectin-positive platelets and chemokines. 20 In addition to the hypercoagulability resulting from monocyte and endothelial cell activation, diabetic patients also show platelet hyperaggregability with increased levels of platelet activation-markers such as P-selectin. 21 Dihydropyridine Ca channel blockers were recently reported to protect the endothelial function of renal resistance arteries in hypertensive rats 22 and mesenteric arteries in circulatory shock rats.…”